One-shot hormone blocker may prevent repeat urinary blockages in men

NCT ID NCT07733934

Not yet recruiting Disease control Sponsor: Antev Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a single injection of teverelix DP, a hormone-blocking drug, can shrink the prostate and improve urinary function in men who recently experienced a first episode of acute urinary retention due to an enlarged prostate. About 126 men aged 45 and older will receive either a 90 mg or 120 mg dose of teverelix DP or a placebo. The study measures changes in prostate volume over 12 weeks and tracks whether participants avoid repeat urinary retention or the need for surgery over a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teverelix DP, a GnRH antagonist given as a single injection
What this could lead to: If effective, a single injection of teverelix DP could shrink the prostate and help men avoid repeat urinary retention or the need for surgery.
What could go wrong: This is an early-phase trial with only 126 participants, so results may not apply broadly. GnRH antagonists can cause side effects like hot flashes and hormonal changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE URINARY RETENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia prostate disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE URINARY RETENTION BENIGN PROSTATE HYPERTROPHY(BPH)

More trials for these conditions

Other studies related to the condition(s) this trial covers.